Inspire To Discontinue Development Of Epinastine Nasal Spray

Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced that its Phase 3 trial with epinastine nasal spray for the treatment of seasonal allergic rhinitis (SAR) did not meet its primary endpoint. "Our analysis of the overall data in this program and the current competitive environment in allergic rhinitis indicate that epinastine nasal spray does not show potential to meet our desired product profile in the United States, " stated Christy L. ...

Write comment to this article:

Subject:

Name:

email or site:

Code: